The Effect of Montelukast Treatment on Elderly Patients Diagnosed with COVID-19
2019-20 coronavirus outbreak
Pandemic
DOI:
10.54005/geneltip.1352153
Publication Date:
2024-08-25T19:01:17Z
AUTHORS (9)
ABSTRACT
Background/Aims: The clinical course in COVID-19 patients can vary from asymptomatic cases to acute respiratory distress syndrome (ARDS), failure and multiorgan dysfunction. Clinical progression is thought be mainly due the release of proinflammatory cytokines. most common symptoms are fever, cough, malaise, shortness breath. Montelukast, which used treatment seasonal allergic rhinitis asthma, has brought its use infection anti-inflammatory cytokine secretion-reducing effect. There many studies literature that montelukast a positive effect on prognosis mortality COVID-19. However, there not enough evaluating efficacy elderly patients. aim our study evaluate laboratory aged 60 over disease, indicate differences literature. Methods: Our research was planned as retrospective, single-center, observational study. medical records 75 who were hospitalized internal medicine clinic Ankara Bilkent City Hospital between September 2021 December 2022 included. Diagnosis confirmed with reverse transcription polymerase chain reaction (RT-PCR) test nasopharyngeal swab. Results: findings results compared received control group. no statistically significant difference two groups terms dyspnea, gastroenteritis oxygen theraphy requirement. need for intensive care unit admission mortality. length hospital stay both groups, it 10.88±7.24 days group 10.51±5.44 group, groups. parameters compared. neutrophil count leukocyte measured before hospitalization found significantly lower patient receiving (p=0.022, p=0.016). No other parameters. Conclusions: Although effects disease literature, similar observed population We did find short-term years older this low population. one first examine therapy geriatric
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....